Present status of treatment in peritoneal metastasis of gastric cancer.
- Author:
Zhefang WANG
1
;
Li CHEN
Author Information
1. Department of General Surgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China. chenli_hz@yahoo.com.
- Publication Type:Journal Article
- MeSH:
Combined Modality Therapy;
Humans;
Peritoneal Neoplasms;
Precision Medicine;
Stomach Neoplasms
- From:
Chinese Journal of Gastrointestinal Surgery
2015;18(2):194-197
- CountryChina
- Language:Chinese
-
Abstract:
Peritoneal metastasis is considered as the end stage of gastric cancer, which is a fatal malignancy without the chance of surgery. No standard regimens are recommended. Routine treatments can not improve the survival of these patients, while multidisciplinary treatments may probably be promising. Aggressive treatments such as cytoreductive surgery, intra-peritoneal chemotherapy and bidirectional chemotherapy are applied to clinical management in recent years. Furthermore, molecular targeted therapy and immune therapy are developed and making individualized treatment possible. Individualized treatment according to clinical characteristics and expression of biomarkers will be the future of peritoneal metastasis of gastric cancer.
